Quality and best practice in medical laboratories: specific requests for autoimmunity testing.

Q1 Medicine Auto-Immunity Highlights Pub Date : 2020-09-03 DOI:10.1186/s13317-020-00134-0
Ulrich Sack, Xavier Bossuyt, Hristina Andreeva, Péter Antal-Szalmás, Nicola Bizzaro, Dimitrios Bogdanos, Elena Borzova, Karsten Conrad, Marie-Agnes Dragon-Durey, Catharina Eriksson, Katarzyna Fischer, Anna-Maija Haapala, Ingmar Heijnen, Manfred Herold, Werner Klotz, Ana Kozmar, Andrea Tesija Kuna, Marcos López Hoyos, Vladimir A Malkov, Lucile Musset, Eszter Nagy, Johan Rönnelid, Yehuda Shoenfeld, Tatjana Sundic, Alexandra Tsirogianni, Raivo Uibo, Maria José Rego Sousa, Jan Damoiseaux
{"title":"Quality and best practice in medical laboratories: specific requests for autoimmunity testing.","authors":"Ulrich Sack, Xavier Bossuyt, Hristina Andreeva, Péter Antal-Szalmás, Nicola Bizzaro, Dimitrios Bogdanos, Elena Borzova, Karsten Conrad, Marie-Agnes Dragon-Durey, Catharina Eriksson, Katarzyna Fischer, Anna-Maija Haapala, Ingmar Heijnen, Manfred Herold, Werner Klotz, Ana Kozmar, Andrea Tesija Kuna, Marcos López Hoyos, Vladimir A Malkov, Lucile Musset, Eszter Nagy, Johan Rönnelid, Yehuda Shoenfeld, Tatjana Sundic, Alexandra Tsirogianni, Raivo Uibo, Maria José Rego Sousa, Jan Damoiseaux","doi":"10.1186/s13317-020-00134-0","DOIUrl":null,"url":null,"abstract":"<p><p>Special conditions associated with laboratory autoimmune testing are not well compatible with recent developments in regulatory frameworks such as EN/ISO 15189 accreditation or in vitro diagnostic medical device regulation (IVD-R). In addition, international recommendations, guidelines and disease criteria are poorly defined with respect to requirements on autoantibody testing. Laboratory specialists from Austria, Belgium, Croatia, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, and The Netherlands collected information, reported national experience, and identified quality issues in relation to autoantibody testing that require consensus on interpretation of the regulatory frameworks and guidelines. This process has been organized by the European Autoimmunity Standardisation Initiative (EASI). By identifying the critical items and looking for a consensus, our objective was to define a framework for, in particular, EN/ISO accreditation purposes. Here, we present a review of current publications and guidelines in this field to unify national guidelines and deliver in this way a European handout on quality control and accreditation for laboratories involved in autoantibody testing. We focus on quality items that can be checked during accreditation visits. Despite various local varieties, we encountered an overwhelming dedication to quality assurance in all contributing countries.</p>","PeriodicalId":8655,"journal":{"name":"Auto-Immunity Highlights","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470612/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Auto-Immunity Highlights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13317-020-00134-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Special conditions associated with laboratory autoimmune testing are not well compatible with recent developments in regulatory frameworks such as EN/ISO 15189 accreditation or in vitro diagnostic medical device regulation (IVD-R). In addition, international recommendations, guidelines and disease criteria are poorly defined with respect to requirements on autoantibody testing. Laboratory specialists from Austria, Belgium, Croatia, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, and The Netherlands collected information, reported national experience, and identified quality issues in relation to autoantibody testing that require consensus on interpretation of the regulatory frameworks and guidelines. This process has been organized by the European Autoimmunity Standardisation Initiative (EASI). By identifying the critical items and looking for a consensus, our objective was to define a framework for, in particular, EN/ISO accreditation purposes. Here, we present a review of current publications and guidelines in this field to unify national guidelines and deliver in this way a European handout on quality control and accreditation for laboratories involved in autoantibody testing. We focus on quality items that can be checked during accreditation visits. Despite various local varieties, we encountered an overwhelming dedication to quality assurance in all contributing countries.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医学实验室的质量和最佳实践:自身免疫测试的具体要求。
与实验室自身免疫测试相关的特殊条件与 EN/ISO 15189 认证或体外诊断医疗器械法规(IVD-R)等监管框架的最新发展并不完全一致。此外,国际建议、指南和疾病标准对自身抗体检测的要求界定不清。来自奥地利、比利时、克罗地亚、爱沙尼亚、芬兰、法国、德国、希腊、匈牙利、意大利、挪威、波兰、葡萄牙、南非、西班牙、瑞典、瑞士和荷兰的实验室专家收集了相关信息,报告了本国经验,并确定了与自身抗体检测有关的质量问题,这些问题需要就监管框架和指南的解释达成共识。这一过程由欧洲自身免疫标准化倡议(EASI)组织。通过确定关键项目并寻求共识,我们的目标是为 EN/ISO 认证等目的确定一个框架。在此,我们对该领域的现有出版物和指南进行了回顾,以统一各国的指南,并通过这种方式为参与自身抗体检测的实验室提供一份关于质量控制和认证的欧洲手册。我们将重点放在认证考察时可检查的质量项目上。尽管各地的情况不尽相同,但我们发现所有参与国都非常重视质量保证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Potential clinical biomarkers in rheumatoid arthritis with an omic approach. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Short-chain fatty acids and intestinal inflammation in multiple sclerosis: modulation of female susceptibility by microbial products? Endogenous mitochondrial double-stranded RNA is not an activator of the type I interferon response in human pancreatic beta cells. Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1